Climb Bio, Inc. (CLYM)
Last updated: 2026-10-21 10:48:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Climb Bio, Inc. (CLYM) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $10.87, with a market capitalization of $558.85M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.64 to $18.33. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$558.85M | |
$10.74 | |
$18.33 | |
$1.05 | |
$10.80 | |
287.00 | |
1.35M | |
-- | |
$18.33 | |
$1.64 | |
-- | |
-- |
Climb Bio, Inc. (CLYM) Pre-Market Stock Price
Climb Bio, Inc. (CLYM) is trading at $10.87 in pre-market trading as of 2026-10-21 10:47:00, up 0.63% ($0.07) from the previous close of $10.80
Pre-market trading shows how investors are pricing CLYM before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Climb Bio, Inc. (CLYM) 7-Day Stock Price Change
Over the past seven days, Climb Bio, Inc. (CLYM) moved from $10.83 to $10.87, representing a gain of 0.35% ($0.04).
The stock traded between $9.61 and $11.15 during the period. The latest price is near the upper end of the 7-day range, indicating range-bound.
The average daily volume was 984.33 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
CLYM 52-Week Price Position
Position in Range: 55.3%
CLYM is currently trading at $10.87, placing it 55.3% of the way from its 52-week low of $1.64 to its 52-week high of $18.33. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Climb Bio, Inc. (CLYM)?
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Climb Bio, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 29 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Climb Bio, Inc. (CLYM) Stock on MEXC
Eligible investors can buy real shares of Climb Bio, Inc. (CLYM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Climb Bio, Inc. (CLYM) stock price today?
2.Is CLYM stock going up or down today?
3.What is CLYM pre-market price?
4.What is CLYM after-hours price?
5.Is CLYM stock trading now?
6.Where does CLYM sit relative to its 52-week high and low?
7.What sector is Climb Bio, Inc. in?
8.What is Climb Bio, Inc.'s market capitalization and where is it listed?
9.How is CLYM valued in terms of P/E ratio and EPS?
10.Does Climb Bio, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
CLYM Stock Calculator
Estimate the value between CLYM shares and USD.
CLYM Shares to USD
1.00 CLYM shares = 10.868 USD
Calculations are estimates based on the latest available price and are for reference only.



